Protecting Scientific Integrity and Public Policy Pronouncements on COVID-19

Michael McAleer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)


The SARS-CoV-2 virus and the associatedCOVID-19disease is a pandemic that has rocked the worldin terms of public health and medical issues, business, economics and finance. Interesting and topical discussions regarding risk management of COVID-19 have been reported in leading business, economics, finance, and medical journals, as well as information and misinformation, intended or not, in the mass media. In this context, protecting the integrity of public policy pronouncements relating to the conduct andoutcomes of scientific clinical trials. In terms of protecting the scientific integrity of clinical trials of COVID-19 patients, it is intentional to determine whether imperfectly collected data on clinical trials are more useful than having no data at all.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalAdvances in Decision Sciences
Issue number1
Publication statusPublished - Mar 2020

Bibliographical note

Funding Information:
* The author acknowledges the financial support of the Australian Research Council and the Ministry of Science and Technology (MOST), Taiwan.

Publisher Copyright:
© 2020 Hindawi Limited. All rights reserved.


Dive into the research topics of 'Protecting Scientific Integrity and Public Policy Pronouncements on COVID-19'. Together they form a unique fingerprint.

Cite this